Skip to main content
    O

    OS Therapies Incorporated (OSTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $0.68
    -0.06 (-8.66%)

    Market Cap: $34.87M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    OS Therapies Incorporated (OSTX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 13, 2026. Financial statements from company filings, amounts in US dollars.

    OS Therapies reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$28.75M, operating cash flow was -$14.24M and free cash flow was -$14.70M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$11.28M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $28.71M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2020 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Cost of revenue$0$0$0$805$1.16M$4.25K
    Gross profit$0$0$0-$805-$1.16M-$4.25K
    Research and development$16.36M$2.84M$3.22M$3.29M$2.17M$0
    Operating income-$28.71M-$6.81M-$4.34M-$4.45M-$4.84M-$5.65K
    Net income-$28.75M-$8.88M-$7.79M-$6.25M-$7.42M-$6.03K
    EBITDA-$27.35M-$5.40M-$1.69M-$4.45M-$4.84M$61.35K
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Gross profit$0$0$0-$124.94K$0$0$0-$1.39K$0$0$0N/A
    Operating income-$9.03M-$8.58M-$10.17M-$11.99M-$6.88M-$4.84M-$5.00M-$2.97M-$2.44M-$779.80K-$630.23K-$1.16M
    Net income-$11.28M-$8.63M-$10.40M-$13.46M-$6.88M-$4.54M-$3.88M-$2.99M-$2.88M-$1.56M-$1.46M-$1.46M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $0 by $269.83K. Shareholder equity was negative, at -$6.10M, as total liabilities of $11.86M exceeded total assets of $6.84M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Total assets$6.84M$5.54M$798.08K$509.11K$325.89K$1.68B
    Current assets$332.91K$5.53M$790.03K$496.83K$312.81K$1.68B
    Cash and equivalents$269.83K$5.53M$38.98K$171.48K$80.79K$1.23B
    Total liabilities$11.86M$4.73M$24.81M$18.07M$11.78M$8.00B
    Short-term debt$0N/A$14.61M$3.04M$1.61B$871.25M
    Long-term debtN/AN/AN/A$10.35M$7.07MN/A
    Shareholder equity-$6.10M-$3.27M-$24.02M-$17.56M-$11.45M-$6.33B
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$8.11M$9.90M$7.30M$6.84M$8.95M$10.31M$4.25M$5.54M$1.98M$1.34M$1.05M$798.08K
    Total liabilities$24.01M$20.74M$17.05M$12.94M$4.25M$3.56M$3.64M$4.73M$2.68M$28.41M$26.56M$24.81M
    Cash and equivalents$431.82K$205.03K$917.55K$269.83K$1.88M$2.80M$2.97M$5.53M$1.86M$94.92K$100.23K$38.98K
    Shareholder equity-$16.97M-$11.91M-$10.82M-$6.10M$3.64M$4.94M-$4.19M$811.49K-$707.13K-$27.06M-$25.51M-$24.02M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Operating cash flow-$14.24M-$7.28M-$3.01M-$3.79M-$4.40M-$2.41B
    Capital expenditures$466.42K$0$0$0$11.93K$2.01M
    Free cash flow-$14.70M-$7.28M-$3.01M-$3.79M-$4.41M-$2.42B
    Dividends paidN/A$31.25MN/AN/AN/AN/A
    Share repurchasesN/AN/A$284.18KN/AN/AN/A
    Investing cash flow-$466.42K$0$1.15K$230.88K$200.47K$158.29M
    Financing cash flow$9.44M$12.78M$2.87M$3.65M$3.05M$3.48B
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$4.65M-$5.53M-$4.56M-$3.73M-$4.71M-$2.36M-$3.44M-$2.37M-$3.38M-$881.19K-$641.73K-$871.16K
    Capital expendituresN/AN/A$0$466.42K$466.42K$316.42K$150.00K$3$0$0$0$19
    Free cash flowN/AN/A-$4.56M-$4.20M-$5.17M-$2.68M-$3.59M-$2.37M-$3.38M-$881.19K-$641.73K-$871.18K
    Last 12 quarters

    Frequently Asked Questions About OSTX

    What is OS Therapies' annual revenue?

    OS Therapies reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is OS Therapies profitable?

    No. OS Therapies reported net income of -$28.75M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does OSTX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$14.24M minus capital expenditures of $466.42K produced free cash flow of -$14.70M.

    How much debt does OS Therapies have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $0 and cash and equivalents of $269.83K.